Insider · CIK 0001838044

Petrova Penka

Reports to the SEC for 1 company · MISSISSAUGA, A6

sec.gov

Transactions

Companies

Filings

CIK

0001838044

Forms 4 and 5

Insider transactions

32 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2021-11-17	Trillium Therapeutics Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Development Officer	DDisposition to Issuer	−140K sh	—	—	0
2021-11-17	Trillium Therapeutics Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Development Officer	DDisposition to Issuer	−84K sh	—	—	0
2021-11-17	Trillium Therapeutics Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Development Officer	DDisposition to Issuer	−49.5K sh	—	—	0
2021-11-17	Trillium Therapeutics Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Development Officer	DDisposition to Issuer	−4,574 sh	—	—	0
2021-11-17	Trillium Therapeutics Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Development Officer	DDisposition to Issuer	−38.8K sh	—	—	0
2021-04-08	Trillium Therapeutics Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+2,708 sh	$0.30	+$818.358	2,708
2021-04-08	Trillium Therapeutics Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+2,604 sh	$3.36	+$8,759.335	5,312
2021-04-08	Trillium Therapeutics Inc.S Sale	Chief Development Officer	SSale	−5,312 sh	$11.09	−$58.9K	0
2021-04-08	Trillium Therapeutics Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−2,708 sh	—	—	83,960
2021-04-08	Trillium Therapeutics Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−2,604 sh	—	—	49,480
2021-03-10	Trillium Therapeutics Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−2,604 sh	—	—	52,084
2021-03-10	Trillium Therapeutics Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+2,708 sh	$0.30	+$815.65	2,708
2021-03-10	Trillium Therapeutics Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+2,604 sh	$3.35	+$8,729.65	5,312
2021-03-10	Trillium Therapeutics Inc.S Sale	Chief Development Officer	SSale	−5,312 sh	$11.08	−$58.9K	0
2021-03-10	Trillium Therapeutics Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−2,708 sh	—	—	86,668
2021-02-09	Trillium Therapeutics Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+508 sh	$9.62	+$4,887.62	508
2021-02-09	Trillium Therapeutics Inc.S Sale	Chief Development Officer	SSale	−508 sh	$14.17	−$7,200.392	0
2021-02-09	Trillium Therapeutics Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−508 sh	—	—	4,574
2021-02-08	Trillium Therapeutics Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−2,604 sh	—	—	54,688
2021-02-08	Trillium Therapeutics Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+2,708 sh	$0.30	+$806.172	2,708
2021-02-08	Trillium Therapeutics Inc.S Sale	Chief Development Officer	SSale	−5,312 sh	$12.65	−$67.2K	0
2021-02-08	Trillium Therapeutics Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−2,708 sh	—	—	89,376
2021-02-08	Trillium Therapeutics Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+2,604 sh	$3.31	+$8,628.875	5,312
2021-01-11	Trillium Therapeutics Inc.S Sale	Chief Development Officer	SSale	−508 sh	$15.21	−$7,725.308	0
2021-01-11	Trillium Therapeutics Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−508 sh	—	—	5,082
2021-01-11	Trillium Therapeutics Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+508 sh	$9.57	+$4,860.087	508
2021-01-08	Trillium Therapeutics Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−2,604 sh	—	—	57,292
2021-01-08	Trillium Therapeutics Inc.S Sale	Chief Development Officer	SSale	−2,604 sh	$15.50	−$40.4K	0
2021-01-08	Trillium Therapeutics Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+2,604 sh	$3.33	+$8,673.924	2,604
2021-01-07	Trillium Therapeutics Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−2,708 sh	—	—	92,084
2021-01-07	Trillium Therapeutics Inc.S Sale	Chief Development Officer	SSale	−2,708 sh	$14.71	−$39.8K	0
2021-01-07	Trillium Therapeutics Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+2,708 sh	$0.30	+$808.88	2,708

Recent filings

Accepted (ET)
Nov 194
Petrova Penka0001104659-21-141740
SEC(opens sec.gov)
Apr 94
Petrova Penka0001062993-21-003541
SEC(opens sec.gov)
Mar 124
Petrova Penka0001062993-21-002674
SEC(opens sec.gov)
Feb 104
Petrova Penka0001062993-21-001199
SEC(opens sec.gov)

Companies

Trillium Therapeutics Inc.Chief Development Officer

Address

C/O TRILLIUM THERAPEUTICS INC. 2488 DUNWIN DRIVE

MISSISSAUGA, A6, L5L 1J9